{"id":4074,"date":"2025-07-11T11:35:06","date_gmt":"2025-07-11T08:35:06","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4074"},"modified":"2025-07-11T13:23:35","modified_gmt":"2025-07-11T10:23:35","slug":"belief-biomed-bbm-d101-gene-therapy-phase-1-2-clinical-trial-nct07058662","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/belief-biomed-bbm-d101-gene-therapy-phase-1-2-clinical-trial-nct07058662\/","title":{"rendered":"D\u00e9but de l&#039;essai clinique de phase 1\/2 de la th\u00e9rapie g\u00e9nique BBM-D101"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Belief BioMed (BBM), dont le si\u00e8ge social est en Chine, est une soci\u00e9t\u00e9 mondiale de biotechnologie innovante int\u00e9grant le d\u00e9veloppement, la fabrication et l&#039;application clinique de produits de th\u00e9rapie g\u00e9nique. L&#039;annonce du lancement des essais de phase 1\/2 de la th\u00e9rapie g\u00e9nique BBM-D101, d\u00e9velopp\u00e9e pour la dystrophie musculaire de Duchenne, a \u00e9t\u00e9 publi\u00e9e sur la page d&#039;accueil de ClinicalTrials.gov (identifiant\u00a0: NCT07058662).<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table des mati\u00e8res<\/h2><nav><ul><li><a href=\"#bbm-d-101-gene-therapy-phase-1-2-clinical-trial\">Essai clinique de phase 1\/2 sur la th\u00e9rapie g\u00e9nique BBM-D101<\/a><\/li><li><a href=\"#bbm-d-101-clinical-trial-nct-07058662\">Essai clinique BBM-D101 \u2013 NCT07058662<\/a><\/li><li><a href=\"#bbm-d-101-phase-1-2-participation-criteria\">Crit\u00e8res de participation \u00e0 la phase 1\/2 de l&#039;\u00e9tude BBM-D101<\/a><\/li><li><a href=\"#how-can-i-contact-with-belief-bio-med\">Comment puis-je contacter Belief BioMed ?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bbm-d-101-gene-therapy-phase-1-2-clinical-trial\">Essai clinique de phase 1\/2 sur la th\u00e9rapie g\u00e9nique BBM-D101<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">L\u2019objectif de l\u2019\u00e9tude est d\u2019\u00e9valuer l\u2019innocuit\u00e9, la tol\u00e9rance et l\u2019efficacit\u00e9 du BBM-D101 pour traiter les participants atteints de dystrophie musculaire de Duchenne.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BBM-D101 est une th\u00e9rapie par addition g\u00e9nique bas\u00e9e sur une cassette g\u00e9n\u00e9tique de prot\u00e9ine th\u00e9rapeutique AAV (Aide vasculaire adaptative) inject\u00e9e dans le muscle pour traiter la DMD. Cette prot\u00e9ine th\u00e9rapeutique pourrait jouer un r\u00f4le m\u00e9diateur dans le complexe prot\u00e9ique associ\u00e9 \u00e0 la dystrophine (DAD) afin de pr\u00e9venir la dystrophie musculaire et de pr\u00e9server la fonction musculaire.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bbm-d-101-clinical-trial-nct-07058662\">Essai clinique BBM-D101 \u2013 NCT07058662<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>D\u00e9but de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2025-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement du primaire (estim\u00e9)<\/strong>: 2027-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2031-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre de participants (estim\u00e9)<\/strong>: 9 (Homme)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Emplacements<\/strong>: Chine<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c2ges admissibles aux \u00e9tudes<\/strong>: 4 ans \u00e0 9 ans (enfant)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bbm-d-101-phase-1-2-participation-criteria\">Crit\u00e8res de participation \u00e0 la phase 1\/2 de l&#039;\u00e9tude BBM-D101<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Les personnes doivent remplir les conditions d&#039;inclusion pour \u00eatre admissibles. Si une personne souffre d&#039;une autre maladie ou suit un traitement susceptible de l&#039;emp\u00eacher de b\u00e9n\u00e9ficier d&#039;une th\u00e9rapie g\u00e9nique, elle pourrait ne pas \u00eatre admissible \u00e0 participer. L&#039;ensemble des crit\u00e8res d&#039;inclusion et d&#039;exclusion est disponible en cliquant sur ce lien. <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07058662\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07058662<\/a> \u2013.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-can-i-contact-with-belief-bio-med\">Comment puis-je contacter Belief BioMed ?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nom<\/strong>: Hanyang Hu<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Num\u00e9ro de t\u00e9l\u00e9phone<\/strong>: +86-021-33588288<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E-mail<\/strong>: huhanyang@beliefbiomed.com<\/p>","protected":false},"excerpt":{"rendered":"<p>Belief BioMed (BBM), headquartered in China, is a global innovative biotechnology company integrating the development, manufacturing and clinical application of gene therapy products. It was announced on the page published on ClinicalTrials.gov with the ID NCT07058662 that the phase 1\/2 trials of BBM-D101 gene therapy developed for Duchenne Muscular Dystrophy will be initiated. BBM-D101 Gene [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4082,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[199,197,123,137,61,389],"class_list":["post-4074","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-bbm-d101","tag-belief-biomed","tag-china","tag-clinical-trial","tag-gene-therapy","tag-nct07058662"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=4074"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4074\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/4082"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=4074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=4074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=4074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}